middle.news
FDA Clearance Moves Percheron's HMBD-002 AML Trial Toward Patients
8:17am on Monday 2nd of November, 2026 AEDT
•
Biotechnology
Read Story
FDA Clearance Moves Percheron's HMBD-002 AML Trial Toward Patients
8:17am on Monday 2nd of November, 2026 AEDT
Key Points
FDA clearance enables the Vanderbilt Health-led US trial to proceed
HMBD-002 to be tested with venetoclax and azacitidine
Study proposed to enrol up to 20 patients with relapsed or refractory disease
Clinical trial material has been manufactured and released
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Percheron Therapeutics (ASX:PER)
OPEN ARTICLE